EyeGate begins ocular drug treatment trial; Stanford debuts wireless, self-propelled delivery device;

> EyeGate Pharma is enrolling patients for a Phase I clinical study evaluating EGP-437 in patients with anterior scleritis, using the company's ocular drug delivery system that wields a low-level electrical current to carry the drug to its target. Release

> Ikaria says it enrolled its last patient 6 weeks early for a pivotal Phase III trial investigating inhaled nitric oxide in premature infants with bronchopulmonary dysplasia. The trial began in December 2009. Release

> Deakin University in Australia, working with The Energy and Resources Institute, is launching a nanobiotechnology center that will focus, in part, on biomedical research, The Times of India reports. Story

> Ada Poon, an assistant professor at the Stanford School of Engineering, has developed a wirelessly powered, self-propelled device small enough to move through the bloodstream to conduct diagnostics, perform surgery or deliver drugs. Release

> OPKO Health has acquired the rights to BioZone's drug delivery platforms in order to improve drug solubility for its own compounds and manufacture the treatments more efficiently and cheaply. Neither side disclosed financial terms. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.